You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

Ebola Clue Lurks in 10 Million Zambian Bats

BLOOMBERG       by  Matthew Hill                        Jan. 12, 2015                                    

At 4:50 a.m. at the Kasanka National Park in northern Zambia, tourists watch from a platform in a tree as the sound of millions of wings accompanies the sunrise.

Straw-coloured Fruit Bats fly in Kasanka National Park, Zambia. Photographer: Fabian von Poser/Getty Images

Meeting / Event Tags: 
Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Extreme measures' needed to see Ebola shot development through

REUTERS     by  Kate Kelland                                          Jan.12, 2015 
LONDON --Developing and bringing to market effective Ebola vaccines requires extreme measures and unprecedented international cooperation, global health experts said on Monday.

A health worker wearing protective gear stands outside a quarantine zone in a Red Cross facility in the town of Koidu, Kono district in Eastern Sierra Leone December 18, 2014.Credit: Reuters/Baz Ratner

In an interim report on a roadmap for vaccines against the current and any future outbreaks of the deadly virus, infectious disease specialists Jeremy Farrar and Mike Osterholm said the scope of effort was "too complex for any single government, organization or company". They called for sustained public-private sector partnership and commitment.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

WHO experts chart next steps for Ebola vaccine trials

CENTER FOR INFECTIOUS DISEASE AND POLICY RESEARCH     by Lisa Schnirring                                 Jan. 9, 2015

The next steps in testing Ebola vaccines as well as a picture of how they might be used in West Africa's outbreak region became clearer today as officials from the World Health Organization (WHO) shared the outcome of yesterday's (Thursday's) high-level meeting in Geneva.

Large phase 3 trials in West Africa's outbreak setting will be next up to see if the vaccines work, with the studies designed to collect more safety data, a task usually covered in phase 2 trials, experts involved in the meeting said today at a WHO media telebriefing. However, as Ebola infections drop off in the outbreak region, scientists face a closing window of opportunity to see how the vaccines perform in a real-life setting.

Experts also signaled a possible role for two Ebola vaccine formulations: a single-dose vaccine providing shorter-term immunity that could be used to tamp down Ebola flare-ups and a prime-boost vaccine that may provide more durable immunity and could be used for other immunization strategies.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

In Africa, a Decline in New Ebola Cases Complicates Vaccine Development

NEW YORK TIMES      by Andrew Pollack                                                           Jan. 9, 2015

As authorities and drug companies hurriedly prepare to begin testing Ebola vaccines in West Africa, they are starting to contemplate a new challenge: whether an ebbing of the outbreak could make it more difficult to determine if the experimental vaccines are effective.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Health 2 Leading Ebola Vaccines Appear Safe, Further Tests Starting

ASSOCIATED PRESS  by Maria Cheng                                                                          Jan. 9, 2015
LONDON --The World Health Organizationsays the two leading Ebola vaccines appear safe and will soon be tested in healthy volunteers in West Africa.

After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines ? one made by GlaxoSmithKline and the other licensed by Merck and NewLink ? have "an acceptable safety profile."

In a press briefing on Friday, Dr. Marie-Paule Kieny, who heads WHO's Ebola vaccine efforts, said "the cupboard (for Ebola vaccines) is filling up rapidly."

She said further trials in healthy people in West Africa, including health workers, are scheduled to start soon. Kieny added several other vaccines were being developed in the U.S., Russia and elsewhere.

Read complete story.
http://abcnews.go.com/Health/wireStory/leading-ebola-vaccines-safe-tests-starting-28107527

Problem, Solution, SitRep, or ?: 

Ebola: vaccine trials can offer ‘signs of hope’ says UN health chief

UNITED NATIONS NEWS CENTRE                                Jan. 8, 2015

GENEVA--The United Nations World Health Organization (WHO) today convened in Geneva its second ever high-level meeting on Ebola vaccines access and financing, to review the current status of clinical trials and plans for Phase II and Phase III efficacy trials.

WHO mobile lab scientists at the crossing point between Guinea and Sierra Leone, two of the countries affected by the Ebola outbreak in West Africa. Photo: WHO/Saffea Gborie

“We are here to take stock, plan the next steps, and make sure that all partners are working in tandem. We all want the momentum and sense of urgency to continue,” Dr. Margaret Chan, Director-General of WHO said as she kicked off the meeting.

The most advanced candidate Ebola vaccine is scheduled to enter Phase III efficacy clinical trials in West Africa in January/February 2015, and if shown effective – will be available for deployment a few months later.

Problem, Solution, SitRep, or ?: 

The Race for the Ebola Vaccine

THE DAILY BEAST  by Abby Haglage                                                                  Jan. 7, 2015

...Although a few smaller companies have become involved in the race for a vaccine, three major pharmaceutical makers are taking the lead—each pursuing a different vaccine. The trials are unprecedented for a variety of reasons, including the rapid timeline (trials of this nature generally take three to four years).

                                                      Steve Parsons-WPA Pool/Getty Images

Each individual race involves an unusual collaboration between researchers, manufacturers, and public-health entities. Together, the teams are working 24 hours a day for a product that promises much higher risk than it does profit.

Here’s what you need to know about the Ebola vaccine front-runners.

Read complete story.

http://www.thedailybeast.com/articles/2015/01/07/the-race-for-the-ebola-vaccine.html

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

J&J, Bavarian Nordic start clinical tests in Ebola vaccine race

REUTERS     by Ben Hirschler                              Jan. 6, 2015
LONDON --Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.

Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. However, the J&J vaccine offers a different approach, since it involves two separate injections.

Read complete story.

http://www.reuters.com/article/2015/01/06/us-health-ebola-vaccine-j-j-idUSKBN0KF0HH20150106

Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 0.856 seconds.